Page last updated: 2024-11-05

thalidomide and Eosinophilia, Pulmonary

thalidomide has been researched along with Eosinophilia, Pulmonary in 1 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pretz, J1
Medeiros, BC1

Other Studies

1 other study available for thalidomide and Eosinophilia, Pulmonary

ArticleYear
Thalidomide-induced pneumonitis in a patient with plasma cell leukemia: No recurrence with subsequent lenalidomide therapy.
    American journal of hematology, 2009, Volume: 84, Issue:10

    Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Pulmonary Eosinoph

2009